Heyholder

This is an amended filing

‹ Activism Filings

Alteogen Inc. Absorption of subsidiary Alteogen Biologics, merger date corrected to Feb 16, 2027

Alteogen Inc.· Material Event ReportAmended

AI summary · Not investment advice

Alteogen absorbs its subsidiary Alteogen Biologics at a ratio of 1 : 0.1679581, and the merger date was changed to February 16, 2027.

Merger ratio

1 : 0.1679581 (Alteogen : Alteogen Biologics)

600,477 new shares to be issued

Key facts

New share listing date
Mar 12, 2027As corrected
Merger counterparty
ALTEOGEN BIOLOGICS, INC.Subsidiary
Merger date
Feb 16, 2027As corrected
Merger method
Alteogen absorbs its subsidiary Alteogen Biologics, Inc. in a merger
Merger type
Small-scale merger
Appraisal rights
Not granted (small-scale merger)
Board resolution date
Oct 6, 2026

Commentary

AI commentary · Not investment advice

What happened

Alteogen decided to absorb its subsidiary, Alteogen Biologics, Inc., in an absorption merger (one company takes over another, which then ceases to exist).

In the company's terms

The exchange ratio is 1 : 0.1679581. The merger creates 600,477 new common shares. It is a small-scale merger. The merger date has been changed to February 16, 2027.

What changes for shareholders

The company being merged had sales of KRW 20.487 billion in the first half of 2026. Its net income for the same period was KRW 6.298 billion.

The notice period for shareholders opposing the merger ran from October 21 to November 4, 2026. Because this is a small-scale merger, appraisal rights (the right of opposing shareholders to sell shares to the company) are not granted. Creditors can file objections from January 15 to February 15, 2027. The merger registration is scheduled for February 17, 2027. The new shares are scheduled to begin trading on March 12, 2027.

Comments

No comments yet

Comments from shareholders will appear here.